The effect of thermoregulation quality improvement initiatives on the admission temperature of premature/very low birth‐weight infants in neonatal intensive care units: A systematic review

2020 ◽  
Vol 25 (2) ◽  
Author(s):  
Denise Donnellan ◽  
Zena Moore ◽  
Declan Patton ◽  
Tom O'Connor ◽  
Linda Nugent
2016 ◽  
Vol 61 (1) ◽  
pp. 90-95 ◽  
Author(s):  
Jadwiga Wójkowska-Mach ◽  
T. Allen Merritt ◽  
Maria Borszewska-Kornacka ◽  
Joanna Domańska ◽  
Ewa Gulczyńska ◽  
...  

2009 ◽  
Vol 98 (9) ◽  
pp. 1433-1436 ◽  
Author(s):  
Mario Rüdiger ◽  
Helmut Küster ◽  
Egbert Herting ◽  
Angelika Berger ◽  
Christoph Müller ◽  
...  

2012 ◽  
Vol 31 (7) ◽  
pp. 691-695 ◽  
Author(s):  
Jadwiga Wójkowska-Mach ◽  
Maria Borszewska-Kornacka ◽  
Joanna Domańska ◽  
Jausz Gadzinowski ◽  
Ewa Gulczyńska ◽  
...  

2013 ◽  
Vol 32 (6) ◽  
pp. 594-598 ◽  
Author(s):  
Jadwiga Wójkowska-Mach ◽  
Agnieszka Chmielarczyk ◽  
Maria Borszewska-Kornacka ◽  
Joanna Domańska ◽  
Janusz Gadzinowski ◽  
...  

PEDIATRICS ◽  
1989 ◽  
Vol 83 (2) ◽  
pp. 244-249
Author(s):  
Janet B. Arrowsmith ◽  
Gerald A. Faich ◽  
Dianne K. Tomita ◽  
Joel N. Kuritsky ◽  
Franz W. Rosa

In April 1984, the US FDA was notified of an unusual clinical syndrome consisting of ascites, liver and renal failure, thrombocytopenia, and death among low birth weight infants exposed to an intravenous vitamin E preparation, E-Ferol. The product, which had not been tested for safety prior to marketing, was voluntarily withdrawn from the market in early April. To further investigate the reported associations, the FDA conducted a retrospective cohort study among seven neonatal intensive care units where the product had been used. Standardized abstraction forms were completed for infants admitted to a unit between Nov 1, 1983, and April 30, 1984. Included in the study were 379 infants weighing 2,000 g or less and surviving at least two days; 148 (39%) had been exposed to E-Ferol. Compared with the unexposed infants, the exposed infants were more likely to die and to have ascites, hepatomegaly, thrombocytopenia, and a combination of clinical events similar to the syndrome initially reported. We conclude that the use of E-Ferol in these neonatal intensive care units was associated with increased morbidity and mortality among exposed infants.


Sign in / Sign up

Export Citation Format

Share Document